Synopsis
Synopsis
0
VMF
0
Listed Dossiers
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Apocard
2. Flcane
3. Flecadura
4. Flecainid Isis
5. Flecainid-isis
6. Flecainide
7. Flecainide Monoacetate
8. Flecainide Monoacetate, (+-)-isomer
9. Flecainide Monoacetate, (r)-isomer
10. Flecainide Monoacetate, (s)-isomer
11. Flecainide, (r)-isomer
12. Flecainide, (s)-isomer
13. Flecainide, 5-ho-n-(6-oxo)-derivative
14. Flecainide, 5-ho-n-(6-oxo)-derivative, (+-)-isomer
15. Flecatab
16. R818
17. Tambocor
1. 54143-56-5
2. Flecainide (acetate)
3. Tambocor
4. R-818
5. Flecainide Monoacetate
6. Flecainide Acetate Salt
7. R 818
8. 54143-56-5 (acetate)
9. N-(2-piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide Acetate
10. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
11. Mls000069675
12. Chebi:5091
13. M8u465q1wq
14. Apocard
15. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, Monoacetate
16. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-,monoacetate
17. N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
18. Smr000058451
19. Acetic Acid;n-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
20. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Acetate
21. Sr-01000000172
22. Einecs 258-997-5
23. Mfcd00214290
24. Unii-m8u465q1wq
25. Flecainidacetat
26. Tambocor (tn)
27. Flecainide Acetate [usan:usp:jan]
28. N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
29. Dsstox_cid_626
30. Opera_id_1587
31. 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidinylmethyl)benzamide Acetate
32. Cas-54143-56-5
33. Dsstox_rid_75700
34. Dsstox_gsid_20626
35. Mls001148177
36. Mls002222300
37. Schembl121583
38. Chembl1200822
39. Dtxsid8020626
40. Flecainide Acetate [jan]
41. Flecainide Acetate (jp17/usp)
42. Flecainide For System Suitability
43. Flecainide Acetate [usan]
44. Flecainide Acetate [vandf]
45. Hms1570c12
46. Hms2097c12
47. Hms2231e15
48. Hms3259f11
49. Hms3267n04
50. Hms3369m07
51. Hms3412d09
52. Hms3676d09
53. Hms3714c12
54. Flecainide Acetate [mart.]
55. 11a-hydroxyepoxyprogesterone
56. Bcp17825
57. Flecainide Acetate [usp-rs]
58. Flecainide Acetate [who-dd]
59. Tox21_200208
60. Akos015889993
61. N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide Acetate
62. Ccg-220735
63. Cs-1400
64. Nc00641
65. Sb19142
66. Flecainide Acetate [ep Impurity]
67. Flecainide Acetate [orange Book]
68. Flecainide Acetate [ep Monograph]
69. Flecainide Acetate [usp Impurity]
70. Ncgc00093934-01
71. Ncgc00093934-02
72. Ncgc00257762-01
73. As-11702
74. Flecainide Acetate [usp Monograph]
75. Hy-17429
76. Db-052497
77. Eu-0100546
78. Ft-0630667
79. En300-51344
80. D00638
81. E-0735
82. F 6777
83. 143f565
84. Sr-01000000172-2
85. Sr-01000000172-4
86. Sr-01000000172-5
87. Sr-01000000172-7
88. Q27089351
89. Flecainide Acetate, British Pharmacopoeia (bp) Reference Standard
90. Flecainide Acetate, European Pharmacopoeia (ep) Reference Standard
91. 2,5-bis(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)benzamide Acetate
92. Flecainide Acetate, United States Pharmacopeia (usp) Reference Standard
93. 2-({[2,5-bis(2,2,2-trifluoroethoxy)benzoyl]amino}methyl)piperidinium Acetate
94. Flecainide For System Suitability, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 474.4 g/mol |
|---|---|
| Molecular Formula | C19H24F6N2O5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 474.15894084 g/mol |
| Monoisotopic Mass | 474.15894084 g/mol |
| Topological Polar Surface Area | 96.9 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 531 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Flecainide acetate |
| Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
| Active Ingredient | Flecainide acetate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 100mg; 50mg; 150mg |
| Market Status | Prescription |
| Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
| 2 of 2 | |
|---|---|
| Drug Name | Flecainide acetate |
| Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
| Active Ingredient | Flecainide acetate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 100mg; 50mg; 150mg |
| Market Status | Prescription |
| Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans
Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Product Name : InRhythm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2024

Details:
Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Flecainide,Amiodarone Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Win Medica | Pharmassist
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2022

Lead Product(s) : Flecainide,Amiodarone Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Win Medica | Pharmassist
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: PhysIQ
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Product Name : InRhythm
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program
Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Product Name : InRhythm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Deerfield Management
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Product Name : InRhythm
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Product Name : InRhythm
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval for the US market.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide
Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Flecainide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Flecainide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ranolazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Ranolazine,Metoprolol Tartrate,Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ranolazine,Metoprolol Tartrate,Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ranolazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2017

Details:
Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Flecainide,Sotalol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Medtronic Plc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2015

Lead Product(s) : Flecainide,Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Medtronic Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Details : Flecainide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2015

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
21
PharmaCompass offers a list of Flecainide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flecainide manufacturer or Flecainide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flecainide manufacturer or Flecainide supplier.
PharmaCompass also assists you with knowing the Flecainide API Price utilized in the formulation of products. Flecainide API Price is not always fixed or binding as the Flecainide Price is obtained through a variety of data sources. The Flecainide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate, including repackagers and relabelers. The FDA regulates Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate supplier is an individual or a company that provides Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate active pharmaceutical ingredient (API) or Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate finished formulations upon request. The Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers may include Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate API manufacturers, exporters, distributors and traders.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate active pharmaceutical ingredient (API) in detail. Different forms of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate DMFs exist exist since differing nations have different regulations, such as Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate DMF submitted to regulatory agencies in the US is known as a USDMF. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate USDMF includes data on Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate Drug Master File in Japan (Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate JDMF) empowers Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate JDMF during the approval evaluation for pharmaceutical products. At the time of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate Drug Master File in Korea (Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate. The MFDS reviews the Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate KDMF as part of the drug registration process and uses the information provided in the Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with KDMF on PharmaCompass.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP of the European Pharmacopoeia monograph is often referred to as a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate Certificate of Suitability (COS). The purpose of a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate to their clients by showing that a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP has been issued for it. The manufacturer submits a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP holder for the record. Additionally, the data presented in the Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate DMF.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with CEP (COS) on PharmaCompass.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate written confirmation (Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate WC) is an official document issued by a regulatory agency to a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate manufacturer, verifying that the manufacturing facility of a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate APIs or Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate finished pharmaceutical products to another nation, regulatory agencies frequently require a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate WC (written confirmation) as part of the regulatory process.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate suppliers with NDC on PharmaCompass.
Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate GMP manufacturer or Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate GMP API supplier for your needs.
A Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CoA (Certificate of Analysis) is a formal document that attests to Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate's compliance with Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate specifications and serves as a tool for batch-level quality control.
Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CoA mostly includes findings from lab analyses of a specific batch. For each Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate EP), Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate USP).